Company / Cash & Equivalents
Oric Pharmaceuticals, Inc. Cash & Equivalents History
FY2019-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Cash & Equivalents
$45.7M
FY2025
5-year range
$23.4M / $226.0M
FY2021-FY2025
Trend
-23.1%
vs FY2024
Sector context
#185 of 207
Health Care
What the data says
Oric Pharmaceuticals, Inc.'s cash & equivalents of $46M is lower than 89% of companies in the Health Care sector (FY2025). Cash & Equivalents has fluctuated over the past 7 years, ranging from $23M in FY2023 to $226M in FY2021.
Based on SEC 10-K filings.
$46M in FY2025 with a 5-year CAGR of -10.3%.
Improved from $23M to $46M over the past 2 years.
Health Care sector context is included.
Cash & Equivalents over time
Growth rates
- 3-Year CAGR
- -11.9%
- 5-Year CAGR
- -10.3%
- 10-Year CAGR
- -
Sector benchmark
Bottom 11% in Health CareTop 89% of 207This company $45.7M Sector average $669.5M
▼
-93.2% below sector average
Key checks
Key Insights
- 5-year CAGR of -10.3%, indicating a declining trend.
- In FY2025, cash & equivalents decreased 23.1% year-over-year.
- Ranks #185 out of 207 companies in the Health Care sector.
- Peak cash & equivalents was recorded in FY2021.
Company context
Key Data Points
- Altman Z-Score 5.96 (safe zone, above 2.9 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Cash & EquivalentsValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $45.7M | -23.1% |
| FY2024 | $59.4M | +154.0% |
| FY2023 | $23.4M | -65.0% |
| FY2022 | $66.8M | -70.4% |
| FY2021 | $226.0M | +188.1% |
| FY2020 | $78.4M | -12.0% |
| FY2019 | $89.2M | - |
| FY2018 | - | - |
As of FY2025 · SEC 10-K · Updated Feb 28, 2026